Clinical trials: Moderate to Severe Cancer Pain, open to volunteers
Cancer Pain
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.
- Trial name
- NCT05265052
- Testing
- 3D1002 (50 mg)(Phase IIa), 3D1002 (100 mg)(Phase IIa), 3D1002 (150 mg)(Phase IIa)
- Volunteers
- 177 people
- Sponsor
- 3D Medicines
Cancer Pain
Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain
This is a Phase Ib/IIa, multicenter, sequential clinical trial evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SSS40 injection in patients with moderate-to-severe bone metastatic cancer…
- Trial name
- NCT07008703
- Testing
- Injection of humanized nerve growth factor (NGF) antibody
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Moderate to Severe Cancer Pain
Effects of Opioid Drugs on Sleep and Emotion in Patients With Moderate to Severe Cancer Pain
This study is a multicenter cross-sectional observational study, aiming to include approximately 200 patients aged 18-75 years who are using hydrocodone sustained-release tablets or oxycodone sustained-release tablets for pain…
- Trial name
- NCT07616648
- Testing
- No intervention
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Irritable Bowel Syndrome (IBS), Pain
Study on Treatment Mechanisms and Efficacy Prediction of Individualized Transcranial Magnetic Stimulation in Adults With Irritable Bowel Syndrome Using Multimodal MRI and High-Throughput Sequencing
The goal of this clinical trial is to explore if "individualized repetitive Transcranial Magnetic Stimulation (TMS)" works to improve symptoms in adults with Irritable Bowel Syndrome (IBS).
- Conditions
- Irritable Bowel Syndrome (IBS), Pain, Depressive Disorder, Major, Moderate
- Trial name
- NCT07345377
- Testing
- Individualized TMS Intervention
- Where
- China
- Volunteers
- 160 people
- Sponsor
- The Affiliated Hospital of Hangzhou Normal University
Cancer Pains
Prospective Randomized Controlled Clinical Study of Acupoint Application With Gutong Plaster in the Treatment of Moderate to Severe Cancer Pain
This clinical trial aims to evaluate the efficacy and safety of acupoint application with Gutong Plaster for treating moderate to severe cancer pain in patients aged ≥18 years with moderate to severe cancer pain (NRS 4-8), ECOG…
- Trial name
- NCT07657390
- Testing
- On the basis of conventional analgesia, patients receive treatment with Gutong Plaster.
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Chronic Pain
A Study to Evaluate the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride Injection in Participants With Moderate-to-Severe Non-Cancer Chronic Pain
This study will evaluate the drug-drug interaction between KL0011034 Injection and Alfentanil Hydrochloride Injection in participants with moderate-to-severe non-cancer chronic pain. The study consists of two parts.
- Trial name
- NCT07751094
- Testing
- KL0011034 injection, Alfentanil Hydrochloride Injection
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- The Third Xiangya Hospital of Central South University
Uterine Fibroids, Endometriosis
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in…
- Trial name
- NCT05862272
- Testing
- Relugolix Combination Tablet
- Where
- 120 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH